Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Xenon Pharmaceuticals Inc.

NASDAQ: XENE · Life Sciences · 4 alerts · CIK 1582313

Share price
$39.26Close, Nov 16
Market cap
$3.86B
Shares outstanding
98.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Xenon Pharmaceuticals Inc. filings on SEC EDGAR ↗

4:33 PM ET 10-Q
Financial Results

Xenon Pharmaceuticals Q3 2026 Results: Net Loss of $110M, Loss Widens

Xenon Pharmaceuticals reported a net loss of $323.5 million for the nine months ended September 30, 2026, compared to $240.6 million in the prior year, driven by increased R&D spending on its lead candidate azetukalner. The company significantly strengthened its balance sheet, ending the period with $1.15 billion in cash, cash equivalents, and marketable securities following substantial common share issuances.

Key figure
Net loss $110M
4:01 PM ET 8-K
Financial Results

Xenon Pharmaceuticals Financial Results

Xenon Pharmaceuticals reported Q3 2026 financial results, highlighting the submission of its New Drug Application (NDA) for azetukalner in focal seizures to the FDA in September 2026. The company ended the quarter with $1.2 billion in cash and marketable securities, providing a projected cash runway into 2029 as it prepares for topline Phase 3 MDD data in December 2026.

Term
Q3 2026

“We've made significant progress advancing azetukalner with our recent NDA submission to the FDA for focal seizures and through ongoing scientific exchange opportunities. We continue to have great confidence in azetukalner’s product profile in epilepsy based on strong efficacy and consistent safety across more than 1,500 patient-years of data, which has been reiterated in conversations with both epileptologists and neurologists.”

Ian Mortimer, President and Chief Executive Officer
9:20 AM ET Form 4
Insider Buying

Xenon Pharmaceuticals CFO Thomas Patrick Kelly Buys $560K of Stock

Thomas Patrick Kelly, CFO, bought 15,000 shares of Xenon Pharmaceuticals Inc. at $37.32 a share, worth $560K in total on Sep 30, 2026. Shares held after the trade: 15,000.

Value
$560K
Shares
15,000
Price
$37.32
Role
CFO
Trade date
Sep 30, 2026
9:19 AM ET Form 4
Insider Buying

Xenon Pharmaceuticals President & CEO Ian Mortimer Buys $1.12M of Stock

Ian Mortimer, President & CEO, bought 30,000 shares of Xenon Pharmaceuticals Inc. at $37.38 a share, worth $1.12M in total on Sep 30, 2026. Shares held after the trade: 49,923 (+150.6%).

Value
$1.12M
Shares
30,000
Price
$37.38
Role
President & CEO
Holding change
+150.6%
Trade date
Sep 30, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.